Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Announces Target Price $170
Barclays Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $164
TD Cowen Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
TD Cowen Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
DaVita Is Maintained at Equal-Weight by Barclays
DaVita Analyst Ratings
Barclays Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $164
Truist Financial Maintains DaVita(DVA.US) With Hold Rating
BofA Securities Initiates DaVita(DVA.US) With Sell Rating, Announces Target Price $145
DaVita Analyst Ratings
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $175
DaVita Analyst Ratings
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Announces Target Price $165
Analysts Conflicted on These Healthcare Names: Autolus Therapeutics (AUTL), DaVita (DVA) and Bruker (BRKR)
Key Takeaways From DaVita Analyst Ratings
UBS Adjusts DaVita Price Target to $175 From $169, Maintains Buy Rating
DaVita Price Target Raised to $175.00/Share From $169.00 by UBS
DaVita Analyst Ratings
Bank of America Securities Sticks to Its Sell Rating for DaVita (DVA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Stevanato Group (STVN) and DaVita (DVA)